Your browser doesn't support javascript.
loading
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.
Shah, Ankoor; Storek, Jan; Woolson, Rob; Pinckney, Ashley; Keyes-Elstein, Lynnette; Wallace, Paul K; Sempowski, Gregory D; McSweeney, Peter; Mayes, Maureen D; Crofford, Leslie; Csuka, M E; Phillips, Kristine; Khanna, Dinesh; Simms, Robert; Ballen, Karen; LeClercq, Sharon; Clair, William St; Nixon, Andrew B; Nash, Richard; Wener, Mark; Brasington, Richard; Silver, Richard; Griffith, Linda M; Furst, Daniel E; Goldmuntz, Ellen; Sullivan, Keith M.
Afiliação
  • Shah A; Department of Medicine, Duke University, Durham, NC, USA.
  • Storek J; Departments of Medicine and Oncology, University of Calgary, Calgary, AB, Canada.
  • Woolson R; Rho Federal System, Durham, NC.
  • Pinckney A; Rho Federal System, Durham, NC.
  • Keyes-Elstein L; Rho Federal System, Durham, NC.
  • Wallace PK; Department of Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Sempowski GD; Department of Medicine, Duke University, Durham, NC, USA.
  • McSweeney P; Department of Hematology/Oncology, Colorado Blood Cancer Institute, Denver, CO.
  • Mayes MD; Department of Medicine, University of Texas, Houston, TX.
  • Crofford L; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
  • Csuka ME; Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
  • Phillips K; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
  • Khanna D; Department of Medicine, University of Michigan, Ann Arbor, MI.
  • Simms R; Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
  • Ballen K; Department of Medicine, University of Virginia, Charlottesville, VA.
  • LeClercq S; Departments of Medicine and Oncology, University of Calgary, Calgary, AB, Canada.
  • Clair WS; Department of Medicine, Duke University, Durham, NC, USA.
  • Nixon AB; Department of Medicine, Duke University, Durham, NC, USA.
  • Nash R; Department of Hematology/Oncology, Colorado Blood Cancer Institute, Denver, CO.
  • Wener M; Department of Oncology, Fred Hutchinson Cancer Research Center.
  • Brasington R; Department of Medicine, University of Washington, Seattle, WA.
  • Silver R; Department of Medicine, Washington University, St. Louis, MO.
  • Griffith LM; Department of Medicine, Medical University of South Carolina, Charleston, SC.
  • Furst DE; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Goldmuntz E; Department of Medicine, University of Washington, Seattle, WA.
  • Sullivan KM; Department of Medicine, University of California, Los Angeles, CA, USA.
Rheumatology (Oxford) ; 61(10): 4155-4162, 2022 10 06.
Article em En | MEDLINE | ID: mdl-35108379
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células Th1 / Antirreumáticos Tipo de estudo: Clinical_trials Idioma: En Revista: Rheumatology (Oxford) Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células Th1 / Antirreumáticos Tipo de estudo: Clinical_trials Idioma: En Revista: Rheumatology (Oxford) Ano de publicação: 2022 Tipo de documento: Article